The Somerset Medical Center patient poisonings and investigation were a succession of unexplained medical crises that exposed deliberate drug administration and drew nurse Amy Loughren into a police inquiry of her friend and colleague Charles Cullen. The cases gathered force through clinical anomalies, medication records, and the pattern of Cullen’s access to patients and drugs. Yet the danger was not immediately legible: Cullen was also regarded as an unusually capable nurse, while the hospital initially sought to resolve the deaths internally.

An emerging pattern

Cullen’s poisonings at Somerset began around the time Loughren became ill, and, once they started, did not stop. The earliest patients he specifically targeted appear to have been seriously ill or elderly. In mid-January, he used Digoxin on sixty-year-old housewife Elanor Stoecker. Two weeks later, on his forty-third birthday, he used Pavulon, a powerful paralytic. He had combined it with other drugs and could not be sure who had died because of his actions or what had killed Joyce Mangini and Giacomino Toto. On March 11, however, he was certain that norepinephrine had caused John Shanagher’s heart to fail. During the resuscitation, Cullen seemed so knowledgeable about which drugs might reverse Shanagher’s collapse that other nurses and even young doctors deferred to him. His reputation as a code expert grew alongside the emergencies.

Michael Strenko’s case made the contradiction especially stark. The twenty-one-year-old Seton Hall computer sciences student had a genetic autoimmune disease, but his parents believed he was improving. Loughren, back at work after pacemaker surgery and bed rest, feared he would not survive; Cullen was certain he would die. Cullen later judged that Digoxin, epinephrine, or some combination had pushed Strenko past the point of recovery. Because Strenko was already dangerously ill, the drugs’ contribution was difficult to separate from the disease. After multiple codes, Cullen gave Strenko’s mother a technically accurate account of what was happening inside her son’s body. She told Cullen to leave. At approximately two in the morning on May 15, after his mother waved away the last shock paddle, Strenko died.

The earlier Saint Barnabas Hospital investigation provided a grim comparison, not the same episode: there, two IV bags tested positive for insulin, and laboratory work showed unusually high levels of insulin that had not been produced by patients’ bodies. At Somerset, Loughren encountered a new insulin-accountability form without being told what had prompted it. She objected that nurses were being asked to estimate how much remained in a vial and electronically sign their guesses, and refused to sign. Her manager would not explain why insulin was being treated with new caution. Loughren did not yet connect the protocol change to the rising number of deaths and emergencies, or suspect Cullen.

Digoxin in the patient rooms

Jin Kyung Han had entered Somerset on June 12 with Hodgkin’s lymphoma and heart disease. Her cardiologist had prescribed small doses of Digoxin, which kept her blood level around 0.63. After an additional dose was ordered on June 13, the cardiologist reviewed her EKG and concluded that Digoxin was not helping her new arrhythmias and might kill her. He discontinued it. Han was not Cullen’s patient when he acted.

On June 14, Cullen arrived half an hour early. After the evening handoff, he used the Pyxis medication system to call up Digoxin, placed an order for his own patient, and canceled it. The drawer opened anyway. He removed two units, entered Han’s room while she slept, and injected Digoxin into her IV line. The dose was eight times what she had previously received, despite the order to stop the drug. He discarded the needle in the sharps bin and left. The dose took effect after his shift. When Cullen returned to work on June 16, Han was still hospitalized: her heart rate had fallen, she had vomited, and a blood test showed Digoxin at 9.94. Her cardiologist ordered an antidote. Han remained unwell but survived.

Reverend Florian Gall’s course initially looked different. He arrived by ambulance with a severe infection, struggling lungs, and failing kidneys, and required both a ventilator and dialysis. His sister, Lucille Gall, visited daily and questioned aspects of his care, including the drugs being given. Cullen resented her scrutiny. Gall’s heart condition led to a Digoxin prescription, but he gradually improved: his pneumonia eased, his heart rhythm stabilized, and he began sitting up, eating, and talking. His family rescinded his Do Not Resuscitate order. The Digoxin was then discontinued.

On the morning of June 28, Gall unexpectedly went into cardiac arrest. Resuscitation failed; his chart recorded his death at 10:10 a.m. His blood showed an extreme Digoxin level. The hospital’s own account of the result was alarming: Gall was not a natural-death case, and he was not the first. Administrators referred to him as Patient 4, a designation that placed his death within a growing series rather than treating it as an isolated tragedy.

The hospital tests the evidence

The response began inside Somerset. The plan was to move quickly and handle the matter internally. Pharmacy was asked to examine Pyxis activity around the Digoxin deaths, while assistant pharmacist Nancy Doherty was assigned to contact the New Jersey Poison Control Center for help calculating the likely doses. The hospital’s question, as presented to Bruce Ruck, was initially framed as a technical one: how much of the heart drug could account for the blood results?

Doherty told Ruck that one patient had suffered Digoxin toxicity in the Cardiac Care Center on June 16, and that another case occurred on the same unit on June 28. Gall’s level had remained low in earlier tests—1.2 on June 20, 1.08 on June 22, then 1.59 and 1.33—before jumping to 9.61 shortly after dawn on June 28. He had received no further Digoxin after doctors stopped it. Ruck said that such a rise between June 27 and June 28 was impossible unless Gall had received more of the drug. Doherty then disclosed that there had been two more patients before those cases. The conversation expanded from a calculation about one patient’s dose into evidence of multiple unexplained toxicities.

Loughren’s changing understanding

For Loughren, the pattern was obscured by Cullen’s everyday helpfulness. He regularly assisted her, and she was glad to see his name on the schedule. She also relied on his skill with after-death care. When a patient died, he washed the body, removed the IV needles and tubes, and wrapped the deceased neatly in the cheap, easily torn plastic shrouds that Loughren struggled to manage alone. His competence and attentiveness had made him a trusted colleague; neither appeared to her as evidence of danger.

That trust began to fracture when a detective showed her a Pyxis printout from the night Gall died. Loughren recognized Cullen’s record and could suddenly imagine that he had done something terrible, though she could not reconcile the possibility with her image of her friend. Her response was bound up with a long history of difficulty trusting others, shaped by childhood abuse and the failure of people around her to respond appropriately when she disclosed it. She had defended Cullen against what she considered unfair accusations. Now the record made that defense untenable, even as she remained unable to resolve the contradiction between colleague and suspect.

The investigation also made her afraid for herself. Nurses whispered and chose sides; some avoided her because everyone knew she was Cullen’s friend and remembered her objections to the insulin-sign-out form. She worried that she might have made a mistake, taken too much of her antianxiety medication, or jeopardized her nursing license. She delayed meeting detectives by calling in sick, then began speaking with them more freely. Cooperation still carried a cost: she feared losing her job, being deceived by investigators, and betraying a friend whose guilt she could not yet accept.

From medication records to a police inquiry

Loughren’s most consequential insight came from reconsidering Cullen’s routine rather than from the Pyxis printout alone. She remembered where he often stood in the cardiac unit: at the end of an isolated L-shaped hallway near the elevator doors, away from the nursing station. He routinely wheeled the portable Cerner computer down the hall after report, and she had assumed he wanted quiet. She now recognized that the position also gave him a view of the pharmacy runner. Cullen would meet the runner, take the delivery tote, and stock the unit. What had looked like a helpful chore could provide access to drugs without requiring a Pyxis transaction. Loughren realized the system’s removal record might not capture every route by which medication reached the unit.

She began helping investigators assemble the broader record. She had told them about Cerner patient charts, which they wanted preserved in full and unaltered; a subpoena was being prepared. Meanwhile, she brought paperwork to the detectives after shifts and reviewed it herself, including material she carried to bed and read again before returning to work. Tim Braun and Danny Baldwin were often working late, and sharing coffee and documents with them helped her feel less alone. She was still a nurse at the hospital, but the investigators were the only people who knew the extent of her cooperation.

By this stage, the case had changed shape. It was no longer just an internal inquiry into abnormal laboratory results or a dispute over how much Digoxin a patient could have received. Han’s discontinued prescription, Gall’s sudden rise after his Digoxin had stopped, the earlier unreported cases, and Cullen’s access to deliveries pointed toward a pattern that the hospital’s medication records might not fully reveal. For Loughren, the same evidence that opened a new investigative path also dismantled the trust on which her working friendship with Cullen had rested.